Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

Genmab A/S (OTCMKTS:GNMSF)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $301.19 and traded as low as $290.00. Genmab A/S shares last traded at $290.00, with a volume of 7 shares.

Genmab A/S Price Performance

The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The business has a 50-day moving average price of $322.22 and a 200 day moving average price of $301.19.

Genmab A/S (OTCMKTS:GNMSF) last announced its earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.